Glyphosate Facts

Transparency on safety aspects and use of glyphosate-containing herbicides in Europe

Menu
Search

Webinars on the safety assessment of glyphosate

November 8, 4:00 PM – 6:00 PM CET
Carcinogenicity of and Epidemiologic research on glyphosate: a look at the evidence

November 10, 4:00 PM – 6:00 PM CET
The genotoxic potential of glyphosate – is glyphosate to be linked with oxidative stress?

November 15, 4:00 PM – 6:30 PM CET
Glyphosate’s reproductive toxicity potential

November 28, 4:00 PM – 6:30 PM CET
Specific target organ toxicity after repeated exposure (STOT-RE) – Does a classification for glyphosate need to be considered?
 

--------------------------
 

Carcinogenicity of and Epidemiologic research on glyphosate: a look at the evidence

November 8, 4:00 PM – 6:00 PM CET

In 2015, the International Agency for the Research on Cancer (IARC) categorised the active substance glyphosate as a ‘Category 2A’ probable human carcinogen. Subsequent reviews by regulatory agencies around the world (EFSA, Food and Safety Commission of Japan, US EPA, New Zealand EPA and Australian Pesticides and Veterinary Medicines Authority) and the WHO’s Joint Meeting on Pesticide Residues (JMPR) reaffirmed the prevailing view that glyphosate is not likely to be carcinogenic to humans. IARC appears to stand alone against the other scientific opinions; consumer markets are confused and concerned.

During this webinar Dr. A. Wallace Hayes and Dr. John Acquavella will assess the scientific arguments at hand and will host a scientific discussion on glyphosate and cancer. While Dr. Hayes will primarily focus on the evidence available in an inordinate number of long term toxicology studies with glyphosate, Dr. Acquavella will review the epidemiologic research that pertains to glyphosate.

________________________

Speaker biographies:

Dr. John Acquavella is currently Professor at the Department of Clinical Epidemiology at Aarhus University (Denmark). Previously John held the subsequent positions of Executive Director & Oncology Therapeutic Area Head of the Center for Observational Research and Executive Director & Head, Global Epidemiology at Amgen Company. Before Joining Amgen Dr. Acquavella was the Epidemiology Group Lead at Monsanto Company and Exxon Biomedical Sciences respectively.

Dr. Acquavella joined industry after years of experience at University of California as Epidemiology group Lead and at the US Environmental Protection Agency (EPA) as epidemiologist.  He was the recipient of many awards such as the American College of Epidemiology Distinguished Service Award in 2009. He is also a past president of the American College of Epidemiology. Dr. Acquavella holds a B.A. in Psychology from the State University of New York in Buffalo (1976), a M.S. in Epidemiology/ Natural Science of the State University of New York in Buffalo (1977) and a Ph.D. in Epidemiology, Roswell Park Memorial Institute, State University of New York in Buffalo (1989).

Dr. Hayes is a toxicologist with more than 35 years’ experience. He consults for a number of companies and government agencies and holds appointments at Harvard University and University of Massachusetts. Previously, he was Vice President at RJR Nabisco with responsibility for the safety of ingredients worldwide. As Corporate Vice-President at Gillette, he had responsibility for safety and regulatory compliance of consumer products, plant safety, environmental stewardship, and quality control. Dr. Hayes has interacted with regulatory bodies worldwide.

 

The genotoxic potential of glyphosate – is glyphosate to be linked with oxidative stress?

November 10, 4:00 PM – 6:00 PM CET

In 2015, the International Agency for the Research on Cancer (IARC) categorised the active substance glyphosate as a ‘Category 2A’ probable human carcinogen.  Subsequent reviews by regulatory agencies around the world (EFSA, Food and Safety Commission of Japan, US EPA, New Zealand EPA and Australian Pesticides and Veterinary Medicines Authority) and the WHO’s Joint Meeting on Pesticide Residues recently issued evaluations contradicting IARC. The alleged mode of action responsible for glyphosate’s ‘probable’ carcinogenicity is genotoxicity and more specifically: the mechanism of ‘oxidative stress’.
During this webinar Prof. David Kirkland and Dr. James Bus will assess the scientific arguments at hand and will host a scientific discussion on glyphosate and genotoxicity. While Prof. Kirkland will primarily focus on the evidence available in the vast amount of standard genotoxicity studies, Dr. Bus will focus on the plausibility of the mechanism of oxidative stress.

______________________

Speaker biographies:

David Kirkland was formerly Vice President of Scientific and Regulatory Consulting at Covance, Harrogate, where he was responsible for the pharmaceutical regulatory affairs group and expert reviews, with particular emphasis on genetic toxicology.  In 2009 he left Covance to work as an independent genetic toxicology consultant. He has a BSc in microbiology (University of London) and a PhD on cell transformation studies (Imperial Cancer Research Fund, awarded by Brunel University).   Following two post-doctoral fellowships at the Institute of Cancer Research (London) he spent 30 years in contract research, at Toxicol Laboratories and Microtest Research Limited which later become part of Covance.  He has extensive experience with regulatory issues relating to genotoxicity data; he has written numerous publications and is a regular podium speaker/chairperson.

He has received several awards:

  • Fellowship of the UK Environmental Mutagen Society (2002)
  • Honorary Professorship of the University of Wales, Swansea (2006)
  • The first Industrial Genotoxicity Group (UKEMS) Distinguished Toxicologist Award (2010)
  • The US Environmental Mutagen Society Alexander Hollaender Award (2010) for scientific contributions to the field of genetic toxicology and for global leadership in the regulation of toxicology testing
  • The Kitashi Mochizuki Award by the Japanese Environmental Mutagen Society (2014) for promotion of international harmonization of genotoxicity tests through the International Workshops on Genotoxicity Testing (IWGT) of which he was chair of the steering committee for 20 years.
  • The Jim Parry award for outstanding contributions to the field of environmental mutagenesis, UKEMS, 2015.

He was Special Issues Editor for Mutation Research, editorial board member of the Journal of Applied Toxicology, past president of the European Environmental Mutagen and Genomics Society (EEMGS) and UKEMS, and a former councilor of US EMGS. David is a member of the UK Government Advisory Committee on Mutagenicity (UK COM), and a member of the Steering Committee of the ILSI/HESI Genetic Toxicology Technical Committee.

Dr. James Bus has over 35 years of toxicology experience of research and evidence-based literature analyses informing potential health risks  associated with chemical and pesticide exposures. He offers chemical specific and strategic toxicology expertise addressing development, stewardship, and regulatory needs to individual industry clients and business consortia and government and non-governmental agencies. Expertise in design, implementation, and interpretation of toxicity tests and mode of action and dose response/exposure evaluations furthering translation of toxicology findings to risk assessment.  Expertise includes target-organ and endpoint-specific modes of action, and specific toxicity of chemicals including chlorinated organics, ethylene glycol and glycol ethers, aromatic derivatives benzene, styrene, Aniline and others, and pesticides such as 2,4-D. http://www.exponent.com/professionals/b/bus-james

During this webinar Prof. David Kirkland and Dr. James Bus will assess the scientific arguments at hand and will host a scientific discussion on glyphosate and genotoxicity. While Prof. Kirkland will primarily focus on the evidence available in the vast amount of standard genotoxicity studies, Dr. Bus will focus on the plausibility of the mechanism of oxidative stress.
 

Glyphosate’s reproductive toxicity potential

November 15, 4:00 PM – 6:30 PM CET

During this webinar Dr. Mark Martens will host a scientific discussion on the state of play with regards to glyphosate and embryo-fetal developmental toxicity effects. Dr. Martens will primarily focus on the vast amount of evidence available in the numerous detailed embryo-fetal developmental toxicity studies in rats and rabbits and will assess the need for classification.

Dr. Mark Martens is a Consultant in preclinical development and toxicology (MMTA bvba). Admitted to the European Register of Toxicology (ERT), Dr. Martens was previously Vice President for pre-clinical development of the virology franchise of Johnson & Johnson.  Prior to his time at J&J, Dr. Martens was in charge of both toxicology agriculture R&D at Monsanto Europe and also acted as Head of Department of toxicology of the Scientific Institute of Public Health in Brussels where he was involved with bodies such as the European Commission, the OECD, IPCS, IARC and ECETOC programmes on chemical risk assessment and toxicology testing. Dr. Martens holds both a Master and PhD in pharmaceutical sciences from the University of Ghent, Belgium where he specialised in toxicology, phytopharmacy, hematology, industrial pharmacy and clinical biochemistry. Dr. Martens has produced numerous publications, presentations and posters in the fields of clinical, forensic, experimental and regulatory toxicology, and drug metabolism and pharmacokinetics. He is also the Co-author of a book on global new drug development (ULLA postgraduate pharmacy series, Wiley-Blackwell, 2014).

 

Specific target organ toxicity after repeated exposure (STOT-RE) – Does a classification for glyphosate need to be considered?

November 28, 4:00 PM – 6:30 PM CET

During this webinar Dr. Martens will examine the need to classify glyphosate for STOT-RE. Dr. Martens will focus on all the evidence available from different animal models (rat -mouse-dog and rabbit) and assess whether the classification criteria have been met. In this assessment the endpoints, the mechanism of toxicity (it is relevance to humans) and the overall weight of evidence will be considered.

Dr. Mark Martens is a Consultant in preclinical development and toxicology (MMTA bvba). Admitted to the European Register of Toxicology (ERT), Dr. Martens was previously Vice President for pre-clinical development of the virology franchise of Johnson & Johnson. Prior to his time at J&J, Dr. Martens was in charge of both toxicology agriculture R&D at Monsanto Europe and also acted as Head of Department of toxicology of the Scientific Institute of Public Health in Brussels where he was involved with bodies such as the European Commission, the OECD, IPCS, IARC and ECETOC programmes on chemical risk assessment and toxicology testing. Dr. Martens holds both a Master and PhD in pharmaceutical sciences from the University of Ghent, Belgium where he specialised in toxicology, phytopharmacy, hematology, industrial pharmacy and clinical biochemistry. Dr. Martens has produced numerous publications, presentations and posters in the fields of clinical, forensic, experimental and regulatory toxicology, and drug metabolism and pharmacokinetics. He is also the Co-author of a book on global new drug development (ULLA postgraduate pharmacy series, Wiley-Blackwell, 2014).

Last update: 17 January 2017